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Abstract 
Individuals living with schizophrenia are 2-3 times more likely to experience type 2 diabetes 
mellitus. Diabetes medication adherence is essential to reduce morbidity and mortality in this 
population. We conducted a meta-analysis of diabetes medication adherence among people 
with schizophrenia, and compared this to those without schizophrenia. A systematic search 
strategy was used to identify all articles reporting adherence to diabetes medications among 
patients with schizophrenia. In total, 10 unique studies reporting data from 33,910 people 
with schizophrenia were included. Random effects meta-analysis showed people with 
schizophrenia adhered to medication on 77.3% of days prescribed (n=32080, 95%CI=73.6%-
81%, I²=99.2%,), and adhered on 4.6% more days per year than those without schizophrenia 
(p<0.01, 95%CI=2.4%-6.7%, I²=92.5%, schizophrenia n=19367, controls=170,853). 
Furthermore, 56% of individuals with schizophrenia (n=33680) were considered “adherent” 
(i.e. >80% adherence over 12-24 month) to diabetes medication, which was significantly 
more than those without schizophrenia (OR=1.34, 95%CI: 1.18-1.52, p<0.01). Factors which 
were positively associated with diabetes medication adherence were age, number of 
outpatient visits, along with multiple medication administration variables. Future prospective 
research should examine diabetes monitoring, medication prescription, and subsequent 
adherence in fully representative samples. Novel interventions for maximizing compliance to 
diabetes medication in this vulnerable population should also be explored.  
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1. Introduction 
Individuals living with schizophrenia are highly susceptible to type 2 diabetes 
mellitus (T2DM) (de Hert et al., 2009). Current estimates show that individuals with 
schizophrenia are 2 to 3 times more likely to acquire T2DM than the general population 
(Stubbs et al., 2015). It is believed that approximately 10 to 15% of individuals with 
schizophrenia have T2DM (Vancampfort et al., 2016). A number of factors contribute to a 
higher T2DM prevalence in this population, including family history, cardio-metabolic side 
effects of antipsychotic medication, and lifestyle factors such as physical inactivity and poor 
diet quality (Stubbs et al., 2015).   
 Higher T2DM prevalence carries a number of health consequences for individuals 
with schizophrenia. Both T2DM and excess weight are independent risk factors for 
developing cardiovascular disease and place individuals with schizophrenia at greater risk of 
early mortality (Ribe et al., 2014). Previous research has demonstrated that as a result of 
cardiovascular disease, individuals with schizophrenia have a shortened life expectancy of 
approximately 10 to 20 years (Ribe et al., 2014). 
 A number of strategies have been recommended for helping individuals with 
schizophrenia to manage T2DM, and to maintain and promote cardio-metabolic health. These 
strategies have primarily focused on lifestyle changes, such as increasing physical activity 
and maintaining a low-calorie and low fat diet (Annamalai and Tek, 2015). Additional 
strategies have included regular blood glucose monitoring and encouraging adherence to 
diabetes medication. Medication adherence can be defined as voluntary involvement of 
taking medication in pursuit of a therapeutic result (Delamater, 2006). Adequate diabetes 
medication adherence can help individuals to maintain glycemic control and reduce the 
likelihood of microvascular complications that result from of diabetes, including blindness, 
renal failure, and amputations (Cade, 2008). In the general population, adherence is 
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determined by multiple factors including: patient-related (younger age, female gender, 
smoking, impulsivity ethnic minority groups), condition-related (the presence of depression 
or other chronic diseases, shorter duration of diabetes, fewer diabetes complications), 
socioeconomic (lack of financial resources/increased medication costs, lower education level, 
lack of family support), health system-related (increased distance to nearest pharmacy, lower 
continuity of care) and therapy-related (concurrent medication use, adverse effects, poor 
previous experience with medication) (World Health Organization, 2003). In comparison to 
the general population, individuals with schizophrenia are less likely to receive diabetes 
education, and less likely to have glycated hemoglobin (HbA1C) and serum lipid levels 
regularly monitored (Cimo et al., 2012; Dickerson et al., 2005; Goldberg et al. 2007). To our 
knowledge, only one previous narrative systematic review has examined diabetes medication 
adherence in people with schizophrenia, and results were limited to only six studies 
(Gorczynski et al., 2014). The purpose of this study was to provide an update on diabetes 
medication adherence in individuals with schizophrenia, and apply meta-analytic techniques 
to obtain an aggregated understanding of diabetes medication adherence rates in people with 
schizophrenia compared to those without. A secondary purpose of this meta-analysis was to 
determine factors associated with medication adherence in people with schizophrenia.  
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2. Methods 
 This systematic review adhered to the PRISMA statement to ensure transparency and 
comprehensive reporting of methodology and results (Moher et al., 2009). The protocol for 
this systematic review adhered directly to the methodology of a previously-published review 
(Gorczynski et al., 2014), only using an updated search to identify more recent studies. The 
statistical analyses were also pre-determined in advance of conducting the review to 
aggregate all eligible data on adherence to anti-diabetic medications in naturalistic settings 
among people with schizophrenia.  
 
2.1 Search Strategy and Selection Criteria 
 All studies included in an earlier systematic review of anti-diabetes medication 
adherence in schizophrenia (Gorczynski et al., 2014) were automatically eligible for this 
meta-analysis. We also performed an updated electronic database search of Cochrane Central 
Register of Controlled Trials, AMED (Allied and Complementary Medicine), Embase, 
MEDLINE, PsycINFO, PsycARTICLES and Ovid MEDLINE using the following keyword 
search terms: “compliance” or “adherence” AND “hypogylcemic agents” or “insulin” or 
“metformin” or “diabetes” AND “psychosis” or “antipsychotic” or “schiz*”. This search was 
conducted from 01/01/2013 – 08/02/2016 in order to update the results of the earlier 
systematic review which used an identical search protocol. The reference lists of retrieved 
articles were searched and a basic search of Google Scholar was conducted using the same 
key words in an effort to identify additional relevant publications.  
 Only peer-reviewed, English-language, original research articles were included in this 
review. We aimed to include all studies which reported adherence to diabetes medications 
among patients with schizophrenia in naturalistic settings as a dependent variable. Our review 
focused on T2DM. Intervention studies reporting adherence rates over the course of a 
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randomized trial were not eligible for inclusion, since medication adherence in clinical trials 
differs significantly from real-life observations.  
Studies were excluded from this review if they failed to report adherence data for 
diabetes medication in schizophrenia or schizophrenia-like disorders. Studies with mixed 
samples of psychiatric disorders were eligible if >80% of the sample had a diagnosis of 
schizophrenia/schizoaffective disorder. Data from studies in which <80% of the sample had a 
confirmed diagnosis of schizophrenia / schizophrenia-like disorders were only included if 
adherence specifically among the patients with schizophrenia / schizophrenia-like disorders 
could be accurately determined and extracted. Where this was not reported, the corresponding 
author of the article was contacted to obtain this information. Studies which did not disclose 
specific diagnoses of the sample were eligible for inclusion provided that the entire sample 
was receiving antipsychotic medications.  
 
2.2 Data Extraction and Analysis 
 Two reviewers (JF and PG) screened the articles independently to assess eligibility. 
Any discrepancies were resolved through discussion between authors until agreement was 
reached. A systematic tool was developed to extract the following information from each 
study:  
(1) Study characteristics: sample size, demographics, location and setting, study design, type 
of medications examined, and measurement methods used. 
(2) Adherence to diabetes medications: (i) mean daily adherence i.e. number of days-per-year 
on which medication was taken as prescribed, and (ii) the number of patients who were 
‘adherent’, defined as achieving >80% adherence to medication regimes (Kreyenbuhl  et al., 
2010). Identical data was also extracted from non-schizophrenia control samples. 
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Additionally, any factors found to be associated with diabetes medication adherence in 
patients with schizophrenia were extracted and systematically reviewed.  
 
2.3 Statistical Analyses 
 Statistical analysis was conducted in OpenMetaAnalyst (Wallace et al., 2009). 
Random-effects models were applied to all meta-analyses in order to account for the variance 
between studies (DerSimonian and Laird , 1986).  
 The primary outcome was the overall daily adherence to diabetes medication regimes 
in people with schizophrenia, as assessed by quantitative measures. Data from all studies 
reporting the number of days-per-year on which medication was taken as prescribed were 
pooled (Wallace et al., 2009), to determine overall adherence. Following this, pooled 
estimates of daily adherence rates in schizophrenia and non-schizophrenia samples were 
compared to estimate the difference in adherence between the two groups.  
 As a secondary outcome, we examined the proportion of schizophrenia patients who 
were ‘adherent’ to diabetes medications (i.e. >80% on objective measures (Kreyenbuhl  et al., 
2010). Therefore, the proportions of adherent patients were pooled across all studies reporting 
this variable, in order to calculate a weighted estimate with 95% confidence intervals. 
Additionally, the numbers of adherent people with schizophrenia was compared to samples 
without schizophrenia using odds-ratio meta-analysis. 
 Variance between studies was assessed using Cochran’s Q and reported as I
2
, which 
quantifies the degree of variance resulting from between-study heterogeneity, rather than by 
chance. The degree of potential publication bias was examined through visual inspection of 
funnel-plots of the association between proportion estimate and SE standard errors and 
Egger’s test for small-study bias. Eligible studies reporting data not able to be pooled for 
meta-analysis were included in the systematic review of study findings.  
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 To assess determinants of diabetes medication adherence, a framework established by 
Gorczynski et al. (2014) was used for this analysis. Independent variables that were shown to 
be significantly associated with diabetes medication adherence (dependent variable) were 
reported to have a statistically positive or negative association. Factors found to have no 
significant association with diabetes medication adherence were reported as null. Factors of 
diabetes medication adherence were separated into the following categories: demographic, 
psychological and cognitive, disease and medical service, and medication. 
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3. Results 
 
3.1 Search results  
The PRISMA search process is presented in Figure 1. The initial database search 
returned 1158 articles, which was reduced to 1000 after duplicates were removed. Of the 216 
articles published since 01/01/2013 (i.e. our previous search Gorczynski et al.(2014)), 204 
were found to be ineligible by title and abstract screening. The 12 remaining articles were 
retrieved in full and screened for eligibility. Of those, 2 met eligibility criteria (Desai et al., 
2014; Simard et al., 2015). Additionally, searching the reference lists of retrieved studies 
identified 2 further studies which were eligible for inclusion in this review (Dixon et al., 
2004; Nelson et al., 2011). Therefore, these 4 articles were added to the 6 studies from our 
original search (Dolder  et al., 2003; Farley et al., 2012; Hansen et al., 2012; Kreyenbuhl et 
al., 2011; Kreyenbuhl et al., 2010; ).  
  
Diabetes medication adherence in schizophrenia 
 
 
 
11 
Figure 1. PRISMA study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Identified through other sources (n = 2) 
Records identified through database 
searching (n = 1158)  
 
Records after duplicated removed 
(n = 1000) Records published before 2013 (n = 784) 
Records from 2013-2016  
(n = 216) 
Full-text articles excluded (n = 10): 
         No adherence data (n = 5) 
         Reporting adherence in RCTs (n=3) 
         Ineligible sample (n = 2) 
 
Articles retrieved in full (n = 12) 
Eligible for review (n = 4) 
Records excluded in title and abstract 
stage (n = 204) 
Included in updated review and meta-
analysis  
(n = 10) 
Articles from the previous review (n= 6) 
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 In total, 10 articles were included in this review, reporting data from 33,910 
psychiatric patients, 94.6% of which had a confirmed diagnosis of schizophrenia / 
schizoaffective disorder. 90.4% were male and the mean age was 53.8 years (median=54, 
range=46-67). Studies’ characteristics are detailed in Table 1. Eight studies were conducted 
through retrospective analysis of medication fill records to provide objective measures of 
compliance. Two studies were conducted through self-report survey measures of adherence. 
All studies were conducted in USA (n=9) or Canada (n=1).  Additional data necessary for 
meta-analyses was obtained from corresponding authors of 4 eligible studies (of 6 authors 
contacted) (Desai et al., 2014; Farley et al., 2012; Kreyenbuhl et al., 2010; Simard et al., 
2015). Funnel plots were generated for each analysis, and visual inspection of these provided 
no indication of publication bias 
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3.2 Daily adherence rates  
 Seven studies reported days-per-year adherence across 32,080 patients with 
schizophrenia (Desai et al., 2014; Dolder et al., 2003; Farley et al., 2012; Hansen et al., 
2012; Kreyenbuhl et al., 2010; Nelson  et al., 2011; Simard et al., 2015). These were 
calculated from prescription fill rates, using medication possession ratios (MPRs), 
Percentage of Days Covered (PDCs), or Cumulative Mean Gap Ratios (CMGRs) over a 1-2 
year period (see Table 1). A random-effects meta-analysis found that people with 
schizophrenia adhered to medication on 77.3% of the days (95% CI=73.6% to 81%, Q=722, 
p<0.01, I
2
=99.2%) (Figure 2). 
 Among these studies, 4 compared daily adherence in 19,367 people with 
schizophrenia to 170,853 people without schizophrenia (Desai et al., 2014; Kreyenbuhl et 
al., 2010; Nelson et al., 2011; Simard et al., 2015). Daily adherence in the non-schizophrenia 
samples was 72.5% (95% CI=66.4% to 78.6%, Q=1365, I
2
=99.78). A comparative meta-
analysis found that those with schizophrenia had a 4.6% higher daily adherence rates than 
people without schizophrenia (p<0.01, 95%CI=2.4%-6.7%, Q=40, p<0.01, I
2
=92.5%), 
equating to approximately 17 more days per-year adherent to medication.   
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 Figure 2. Percentage overall adherence (by fill rates) 
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 3.3 Proportion of adherent patients 
  Six studies used prescription fill records from 33,680 patients with schizophrenia to 
determine the proportion who were ‘adherent’ (i.e. with at least 80% of days covered by 
medications) over a 12-month or 24-month timeframe (Desai et al., 2014; Farley et al., 2012; 
Hansen et al., 2012; Kreyenbuhl et al., 2010; Kreyenbuhl et al., 2011; Nelson  et al., 2011; 
Piette et al., 2007; Simard et al., 2015). In total, 57.6% of patients with schizophrenia were 
adherent to diabetes medications (N=6, n=33,680; 95% CI=48.5%-66.5%, Q=1243, p<0.01, 
I
2
=99.6%). Three of these studies compared the numbers of people reaching 80% adherence 
in samples with schizophrenia against samples without schizophrenia (Desai et al., 2014; 
Kreyenbuhl et al., 2010; Simard et al., 2015). In the non-schizophrenia samples, 46.3% of 
people were classified adherent to anti-diabetic medications (n=170,791, 95% CI=25.7% to 
67.0%, Q=3249.8, I
2
=99.93). A comparative odd-ratio meta-analysis found that people with 
schizophrenia (n=19,305) were significantly more likely than people without schizophrenia 
and diabetes (n=170,791) to be adherent to diabetes medication (OR=1.34, 95% CI=1.18-
1.52, p<0.01). 
  This difference was also consistently observed within the studies, as all 3 
independently observed that people with schizophrenia were significantly more likely to 
achieve >80% adherence than their control samples (Desai et al., 2014; Kreyenbuhl et al., 
2010; Simard et al., 2015). One further study using self-report measures (and thus not 
included in the meta-analysis) (Kreyenbuhl et al., 2011) also found that people with 
schizophrenia were more likely to be adherent over the previous week than people without 
mental illness.   
 
3.4 Determinants of diabetes medication adherence 
  Overall, diabetes medication adherence was positively associated with younger age, 
a higher number of outpatient visits, higher copayments, larger portions of prescriptions 
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filled, and independent medication administration. Factors that negatively affected medication 
adherence included race (black), homelessness, low motivation, difficulties with memory, 
medical co-morbidity, smaller portions of filled prescriptions, and fewer days of medication 
being issued. Mixed results were found for prior hospitalizations, adherence to antipsychotic 
medication, medication regimen complexity, and increased number of drug classes. Full 
results can be found in Table 2.  
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Table 2. Correlates of diabetes medication adherence in schizophrenia 
Determinant Positive 
association 
Negative 
association 
Null 
Demographic Factors 
 
   
Age Desai. 2014 
(N=1821) 
Kreyenbuhl. 2010 
(N=11454) 
Kreyenbuhl. 2011 
(N=44) 
  
Gender (male)   Desai. 2014 
(N=1821) 
Dolder. 2003 (N=24) 
Homelessness  Kreyenbuhl. 2010 
(N=11454) 
 
Married   Kreyenbuhl. 2010 
(N=11454) 
Race (black)  Kreyenbuhl. 2010 
(N=11454) 
 
Race (unknown)   Kreyenbuhl. 2010 
(N=11454) 
Psychological and 
Cognitive Factors 
   
Beliefs about medication 
necessity 
  Kreyenbuhl. 2011 
(N=44) 
Concerns about adverse 
effects  
  Kreyenbuhl. 2011 
(N=44) 
Cognitive impairment   Kreyenbuhl. 2011 
(N=44) 
Motivation barriers  Kreyenbuhl. 2011 
(N=44) 
 
Recall barriers  Kreyenbuhl. 2011 
(N=44) 
 
Disease and Medical 
Service Factors 
   
Alcohol / Substance use 
disorder 
 Kreyenbuhl. 2010 
(N=11454) 
 
Depression  Kreyenbuhl. 2011 
(N=44) 
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Prior hospitalisations  Piette. 2007 
(N=1686) 
Kreyenbuhl. 2010 
(N=11454) 
Medical comorbidity  Kreyenbuhl. 2010 
(N=11454) 
 
Number of outpatient 
clinic visits 
Kreyenbuhl. 2010 
(N=11454) 
Piette. 2007 
(N=1686) 
  
PTSD   Kreyenbuhl. 2010 
(N=11454) 
 
Medication Factors    
<50% prescription 
copayment 
  Kreyenbuhl. 2010 
(N=11454) 
>50% of prescription 
copayment 
Kreyenbuhl. 2010 
(N=11454) 
  
<50% of prescription  
 
Piette. 2007 
(N=1686) 
 
>50% of prescription Kreyenbuhl. 2010 
(N=11454) 
  
> 60 days of medication   Kreyenbuhl. 2010  
(N=11454) 
Piette. 2007  
(N=1686) 
< 60 days of medication  Desai. 2014 
(N=1821) 
Piette.(2007) 
 
Adherence to 
antipsychotics 
Hansen. 2014 
(N=12349) 
Nelson. 2011 
(N=62) 
Farley. 2012 
(N=340) 
Kreyenbuhl. 2011 
(N=44)  
 
Filled prescriptions for one 
med vs. two 
 Piette. 2007 
(N=1686) 
 
Independent medication 
administration 
Kreyenbuhl. 2011 
(N=44) 
  
Medication access barriers  Kreyenbuhl. 2011 
(N=44) 
 
Medication regimen 
complexity 
Kreyenbuhl. 2010 
(N=11454) 
 Kreyenbuhl. 2011 
(N=44) 
Number of drug classes Piette. 2007 
(N=1686) 
 Dolder. 2003 (N=24) 
Kreyenbuhl. 2011 
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(N=44) 
Prescribed insulin   Kreyenbuhl. 2011 
(N=44) 
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4. Discussion 
  The purpose of this systematic review was to provide the first meta-analysis 
investigating diabetes medication adherence in individuals with schizophrenia and compare 
this with the general population.  Results showed that, overall, people with schizophrenia 
were adherent to their diabetes medication on 77.3% of days. People with schizophrenia also 
adhered to medication on 17 more days per-year than controls without schizophrenia. For 
studies that examined proportions of patients who were ‘adherent’ (i.e. >80% compliance 
over a 12- or 24-month period), 57.6% of individuals with schizophrenia were deemed 
adherent. Furthermore, they were 1.34 times more likely to be adherent to diabetes 
medication when compared to individuals without schizophrenia.  
The results of this meta-analysis build upon existing knowledge about diabetes 
medication adherence in people with schizophrenia (Gorczynski et al., 2014). Although 
examining fewer studies and without meta-analytic techniques, this previous review found 
that adherence rates were between 51-85%, (as assessed by objective measures). Factors that 
were positively associated with diabetes medication adherence were increased number of 
outpatient clinic visits, > 50% prescription copayments, > 50 prescription refills by mail, 
adherence to antipsychotic medication, and independent medication administration.  
Previous evidence shows that the physical health of people with schizophrenia is often 
neglected, and they are less likely to receive appropriate medications for cardiometabolic 
disroders (Mitchell et al., 2012). Despite this, the results from this meta-analysis are 
encouraging, showing that those who do receive diabetes treatment adhere better than the 
general population. This challenges the ‘therapeutic nihilism’ which often remains towards 
physical health care of people with schizophrenia, and reinforces the value of routine 
cardiometabolic screening and interventions in mental health services (Lambert and 
Newcomer, 2009).  
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However, it should be acknowledged that diabetes medication adherence rates in the 
general population and those living with schizophrenia are very similar overall, with many 
shared factors affecting medication adherence, including having experience being adherent to 
other forms of medication and being older.   For instance, a recent meta-analysis conducted 
by Iglay et al. (2015) found that daily diabetes medication adherence (MPR) was 75.3% in the 
general population (Iglay et al., 2015); which is only slightly less than the 77.3% adherence 
we observed in the schizophrenia population. This is also the case when comparing these 
findings to other reviews of diabetes medication adherence in the general population. Cramer 
and colleagues found daily medication adherence to be 58% over the previous 12 months 
(Cramer et al., 2008), and Odegard and Capoccia (2007) found mean medication adherence 
rates between 31 and 87%.   
Results also showed that a significant proportion of people with schizophrenia remain 
non-adherent to diabetes medications. Understanding factors that influence medication 
adherence could improve overall care, and guide healthcare professionals to increase the 
likelihood of treatment success (Curkendall et al., 2013). Factors shown to influence diabetes 
medication adherence in the general population include patient’s understanding of the 
importance and benefits of treatment, perceived regime complexity, and emotional well-being 
(Rubin, 2005) – all of which could feasibly be even greater issues for people with 
schizophrenia. Further exploring the behavioural and environmental determinants associated 
with diabetes medication adherence in schizophrenia would inform the creation of rigorous 
interventions (e.g. providing patients with detailed instructions and concrete problem-solving 
strategies such as reminders, self-monitoring tools, cues, reinforcements) (El-mallakh and 
Findlay et al., 2015). For instance, a review by El-Mallakh and Findlay (2015) points to 
various family and clinician support services that are available to help patients with 
schizophrenia better adhere to their medication (Zygmunt et al., 2002). These services include 
multi-cultural education workshops, mobile- and computer-based technologies, reminder 
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phone calls, motivational interviewing, cognitive behavioural therapy, as well as home visits. 
However, medication adherence rates following such interventions vary, with not all 
interventions showing long-term success (Zygmunt et al., 2002).  Additionally, all 
intervention trials pertained to anti-psychotic medication rather than diabetes medication. 
Since the physical healthcare of people with schizophrenia is often neglected, theory-driven 
interventions that take into account determinants known to be associated specifically with 
diabetes medication adherence in this population are urgently needed.   
  Although this review provides the first meta-analytic summary of diabetes 
medication adherence in schizophrenia, several limitations should be noted. First, every effort 
was made to contact study authors by email for additional study details, however some 
authors did not respond, thus excluding some study data from the meta-analyses, and leaving 
insufficient data for meta-regression analysis of variables which might predict medication 
adherence (age, gender, etc.). However, regardless of data eligibility, all relevant studies 
examining diabetes medication adherence were systematically reviewed, along with any 
reported factors associated with adherence, to provide a more thorough overall understanding 
of diabetes medication adherence.  
Second, many studies relied on medication possession ratios (MPR) as proxies for 
medication adherence, which does not fully confirm whether participants actually ingested 
their medication. Despite this limitation, MPR is still widely used as an indirect measure for 
medication adherence (Kreyenbuhl et al., 2010), and by comparing MPRs across 
schizophrenia and other samples, meaningful conclusions can be obtained (Kreyenbuhl et al., 
2010). Furthermore, a strength of this review is that all meta-analytic findings were based on 
objective measurements (e.g. medication possession and prescription fill rates), as only two 
studies used subjective (self-report) measures of adherence; one for daily adherence (Dixon et 
al. 2004), one for number of adherent patients (Kreyenbuhl et al. 2011) - and thus were not 
suitable for inclusion in meta-analyses.  
Diabetes medication adherence in schizophrenia 
 
 
 
25 
A third limitation is that several of the included studies examined diabetes 
medication adherence only in older men who are affiliated with Veterans Affairs living in 
the USA. Such sampling limits the generalizability of our findings to younger individuals, 
women, and those with or without access to other healthcare systems. Caution should be 
taken when interpreting our results given these sampling compositions.   
  A final limitation is the statistical heterogeneity found in all of the meta-analyses 
conducted on adherence data (as indicated by significant Cochran’s Q values and high I
2
 
values). This degree of statistical heterogeneity is perhaps surprising, given that most of the 
included studies used similar samples, measures, locations and time-frames to examine 
medication adherence. Although the between-study heterogeneity was accounted for by the 
random-effects models used when computing our proportional estimates, further investigation 
is required to determine which underlying factors may drive the differences in adherence to 
diabetes medications across different samples of people with schizophrenia. Furthermore, 
despite the statistical heterogeneity identified in our analyses, the reasonably narrow 95% 
confidence intervals (i.e. 73.6% - 83% daily adherence rates found among people with 
schizophrenia; 2.4 - 6.7% higher than general population) is a strength of the findings, as is 
the consistency of findings at study-level. For instance, all 3 studies which compared numbers 
of ‘adherent’ patients in schizophrenia vs. non-schizophrenia samples found that people with 
schizophrenia were significantly more likely to be adherent than control samples (Desai et al., 
2014; Kreyenbuhl et al., 2010; Simard et al., 2015)). 
It should also be considered that people with schizophrenia are significantly less likely 
to be prescribed appropriate medications for their physical health conditions (Piette et al., 
2007). Therefore, the schizophrenia samples used in these analyses may mostly represent 
those patients with more severe diabetes symptoms, or longer course of illness. There was 
insufficient data reported by the studies to examine diabetes illness duration, and no 
information on the frequency of diabetes monitoring for the samples studies. Additionally, all 
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of the studies used retrospective methods to assess adherence. Future research should utilize 
prospective designs, while also measuring the frequency of physical health assessments and 
medications prescriptions in people with schizophrenia. Specifically, researching these 
aspects of physical health care among people in the early stages of psychosis (or recently 
initiating antipsychotic treatment) would provide novel insights into uptake and adherence of 
diabetes medications in schizophrenia. 
  In conclusion, our results suggest that diabetes medication adherence in individuals 
with schizophrenia is higher than those in the general population. Other meta-analyses 
examining diabetes medication adherence in those without schizophrenia support these 
findings. However, diabetes medication adherence for individuals with schizophrenia is still 
insufficient, and theory based strategies are needed to address this in order to improve 
physical health outcomes, given the current inequalities experienced by this patient group. 
Left untreated, diabetes medication non-adherence can have profound consequences on 
patient morbidity and mortality. Thus, prospective research is now needed to examine the 
efficaciousness and effectiveness of diabetes medication adherence interventions.  
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Highlights 
· Individuals living with schizophrenia are highly susceptible to type 2 diabetes mellitus 
· Diabetes medication adherence is essential to reduce morbidity and mortality 
· Individuals with schizophrenia are less likely to receive diabetes education, and less likely 
to have glycated hemoglobin (HbA1C) and serum lipid levels regularly monitored 
· individuals with schizophrenia are more adherent to diabetes medication than those without 
schizophrenia 
· Diabetes medication adherence in individuals with schizophrenia is influenced by age, 
number of outpatient visits 
 
 
 
